Neuren Royalties Jump 23% as DAYBUE Hits US$101M in Fastest Growth Since 2024
DAYBUE delivers US$101 million in Q1 sales as Neuren royalties climb 23%
Neuren Pharmaceuticals reported US$101 million in DAYBUE net sales for Q1 2026, representing 20% year-on-year growth from Q1 2025 and marking the highest year-on-year growth rate since Q3 2024. The result translated to US$10.4 million in royalty income for Neuren, up 23% from Q1 2025, as partner Acadia Pharmaceuticals reaffirmed full-year 2026 DAYBUE net sales guidance of US$460–490 million, implying full-year royalty income for Neuren of US$50–54 million (approximately A$70–77 million at an AUD/USD exchange rate of 0.70–0.72).
The Q1 performance demonstrates DAYBUE’s commercial momentum is accelerating, with sales growth flowing directly through to Neuren’s earnings. The royalty increase outpaced sales growth, reflecting the tiered royalty structure that sees Neuren earn higher percentage rates as DAYBUE sales volumes increase. Acadia’s reaffirmed full-year guidance supports the trajectory, implying approximately 18–25% sales growth for calendar year 2026 and corresponding royalty upside for Neuren.
When big ASX news breaks, our subscribers know first
What are pharmaceutical royalties and why do they matter?
Neuren developed trofinetide (sold as DAYBUE) and granted exclusive worldwide commercialisation rights to Acadia Pharmaceuticals under a licensing agreement. Under this structure, Neuren receives 10% of DAYBUE net sales up to US$250 million and 12% of net sales between US$250 million and US$500 million in North America, with similar tiered rates applying to international markets.
This royalty model allows Neuren to monetise its drug development without bearing commercialisation costs. Acadia handles all sales, marketing, and distribution activities, while Neuren earns revenue as DAYBUE sales grow. The arrangement creates a cash-generative asset without operational overhead, providing capital-efficient exposure to DAYBUE’s market success. As sales volumes push deeper into the higher royalty tiers, Neuren’s percentage take increases, creating leverage to DAYBUE’s commercial expansion.
DAYBUE STIX launch signals expansion of treatment-eligible patients
DAYBUE STIX, a new powder formulation of trofinetide, was launched on a limited basis in Q1 2026 through Rett syndrome Centers of Excellence (COEs) before becoming broadly available across the US in early April 2026. The limited launch generated more than 250 STIX prescriptions during Q1, with approximately 30% of these prescriptions written for treatment-naïve patients or patients who had previously discontinued treatment.
Caregiver satisfaction exceeded 80%, and healthcare professionals provided strong endorsement of the new formulation. The uptake among new and returning patients represents incremental demand beyond the existing liquid formulation market, suggesting STIX addresses a distinct patient need rather than simply cannibalising existing DAYBUE sales.
Jon Pilcher, CEO
“This was a strong start to the year for DAYBUE. I am very encouraged by the initial uptake and enthusiasm for DAYBUE STIX following the limited launch in Centers of Excellence (COEs) and I look forward to seeing the impact of the recent broader US launch.”
The formulation’s ability to attract 30% of prescriptions from patients not currently on treatment indicates STIX could materially expand the addressable patient population. As the broader US rollout progresses through Q2 2026, the impact on overall DAYBUE sales and Neuren’s royalty income will become clearer.
Market penetration points to further growth runway
Current market penetration rates indicate substantial untapped demand remains in the US market. Pilcher noted penetration sits at approximately 60% in Centers of Excellence and approximately 28% in the broader community. The sub-30% penetration in the broader community, where the majority of Rett syndrome patients receive care, suggests significant upside potential for continued sales growth beyond current levels.
Outside the US, contributions from Named Patient Supply programmes continued to grow during Q1 2026. These programmes provide access to trofinetide in jurisdictions where regulatory approval has not yet been secured, generating incremental royalty income while building physician familiarity ahead of potential formal launches.
Expert consensus and global expansion catalysts ahead
A Delphi expert consensus panel recently recommended DAYBUE as part of the standard of care for eligible patients with Rett syndrome (Prange EO et al., Ann Child Neurol. 2026). Inclusion in standard of care guidelines typically supports physician adoption and payer reimbursement, as treatment protocols become embedded in clinical practice and insurance coverage decisions. The endorsement provides clinical validation that could accelerate penetration in the broader community, where uptake has lagged behind specialist centres.
Two near-term catalysts present potential market expansion opportunities:
-
Japan trofinetide trial — enrolment accelerated during Q1 2026, with topline results now expected in the September to November 2026 timeframe, brought forward from the previous Q4 2026 / Q1 2027 guidance.
-
Europe reexamination — the trofinetide reexamination process is expected to conclude in June 2026, following an initial regulatory setback.
Both readouts represent potential catalysts that could unlock new royalty streams beyond North America. Japan represents a significant market opportunity, while European approval would provide access to multiple national markets. Positive outcomes in either jurisdiction would diversify Neuren’s geographic royalty base and reduce concentration risk.
DAYBUE sales trajectory and royalty growth
The commercial trajectory since DAYBUE’s US launch in April 2023 demonstrates consistent growth across both net sales and royalty income. The following table illustrates the progression from the partial 2023 launch year through to 2026 guidance:
| Period | DAYBUE Net Sales (US$m) | Neuren Royalty (US$m) |
|---|---|---|
| CY2023 (Apr-Dec) | 177 | 18 |
| CY2024 | 348 | 37 |
| CY2025 | 391 | 42 |
| CY2026 Guidance | 460–490 | 50–54 |
Q1 2026 sales of US$101 million compared to US$85 million in Q1 2025, representing the 20% year-on-year growth reported. The quarterly progression shows DAYBUE achieved net sales of US$76 million in Q1 2024, US$91 million in Q2 2024, US$85 million in Q3 2024, and US$96 million in Q4 2024, before posting US$85 million, US$97 million, US$110 million, and US$101 million across the four quarters of 2025.
The CY2026 guidance range of US$460–490 million implies approximately 18–25% sales growth from the US$391 million achieved in CY2025. The corresponding royalty guidance of US$50–54 million represents similar percentage growth from the US$42 million earned in CY2025, demonstrating how the tiered royalty structure provides leverage to sales expansion.
The next major ASX story will hit our subscribers first
Neuren’s pipeline and corporate positioning
Beyond DAYBUE, Neuren is advancing its second drug candidate, NNZ-2591, through clinical development for multiple neurodevelopmental disorders. The compound has achieved positive Phase 2 results in Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome. Each programme has received orphan drug designation in the United States and European Union, as well as Fast Track and Rare Pediatric Disease designations from the FDA.
Neuren is currently conducting a Phase 3 clinical trial (“Koala”) evaluating the safety and efficacy of NNZ-2591 in children aged 3 to 12 years with Phelan-McDermid syndrome, alongside a 52-week open-label extension study. The company is also developing NNZ-2591 for the treatment of hypoxic ischaemic encephalopathy (HIE), a serious condition caused by brain injury before or shortly after birth.
The royalty income stream from DAYBUE provides Neuren with a self-funding mechanism to advance NNZ-2591 through clinical development without immediate capital raising requirements. The anticipated A$70–77 million in royalty income for calendar year 2026 creates financial flexibility to pursue multiple clinical programmes simultaneously while building cash reserves.
The Q1 2026 results delivered on multiple fronts: 20% sales growth, 23% royalty growth, successful STIX launch with 30% of prescriptions from new or returning patients, and accelerated Japan trial timelines. Near-term catalysts include Japan topline data in the September to November 2026 timeframe and conclusion of the Europe reexamination process in June 2026. With penetration in the broader US community sitting at approximately 28%, substantial upside remains in the core market while global expansion opportunities develop across multiple jurisdictions.
Want the Next Biotech Breakout in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX biotech and healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving market-moving announcements the moment they hit the ASX, with expert coverage already done for you.